Phase Ib/IIa trial is to evaluate the efficacy of VES001 in asymptomatic patients with gene mutations that cause frontotemporal dementia A total of six participants have been enrolled in the trial across two sites – one in the Netherlands and one in the United Kingdom Copenhagen, Denmark, 09 May 2025 – Vesper Bio ApS (“Vesper” […]
Cohort 7 of the clinical trial of HDP-101 in multiple myeloma safe and well tolerated Cohort 8 expected to start soon Clinical development of the second ADC program HDP-102 in patients with non-Hodgkin lymphoma (NHL) has started Amendment of contract with HealthCare Royalty; payment of USD 20 million significantly extends cash reach Ladenburg, Germany, 24 […]
Enrolment completed – 120 patients with end-stage renal disease in 22 centers in Europe Primary endpoint readouts anticipated in Q2 2025, first market approval expected in 2026 Capability to obtain market approval is further strengthened with the appointment of Rob Eyers as Chief Technology Officer. EINDHOVEN, The Netherlands, 7 January 2025 – Xeltis, a leading […]
Dosing of VES001 has commenced in patients with causal gene mutations for FTD(GRN), a type of frontotemporal dementia which is invariably fatal This follows Vesper having received clinical trial authorisation from the Netherlands and the United Kingdom to initiate its Phase Ib/IIa “SORT-IN-2” trial VES001 is a first-in-class, potentially disease-modifying, orally-dosed, brain-penetrant treatment for FTD(GRN), […]
Copenhagen, Denmark – October 9, 2024 – Antag Therapeutics, a leading biopharmaceutical company focused on targeting the Glucose-Dependent Insulinotropic Polypeptide (GIP) receptor to pioneer novel treatments for obesity, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for its lead molecule, AT-7687. This milestone enables Antag […]
